🌍 FDA-Approved, Globally Impactful. For the first time in history, the FDA has approved an Investigational Device Exemption (IDE) human clinical trial for transcontinental robotic telesurgery—and it was led by Dr. Vipul Patel Vipul Patel, MD, Executive Director of the Society of

Genomic landscape of non-muscle invasive #BladderCancer from #UROMOL Consortium. Lars Dyrskjøt Aarhus Universitet and Ashish M. Kamat, MD, MBBS MD Anderson Cancer Center break down a comprehensive molecular analysis of #NMIBC: 🔬 438 tumors 🧬 33 mutated genes 📈 15% show whole genome doubling — linked to poor

WATCH🎥: Sandip Prasad, MD, MPhil, details key findings from the phase 3 ENVISION trial, which supported the approval of mitomycin intravesical solution in LG-IR-NMIBC. #blcsm urologytimes.com/view/sandip-pr…

How many more times before you say “Enough” ?

When someone is diagnosed with cancer, the road to recovery is never theirs alone. At Medanta, we fight this battle with you—with expertise, compassion, and the reassurance that you are never alone. #JaantaHaiMedanta

Happy Diwali everyone!

A dream come true moment -New #DaVinci console surgeon in making!😍 Excited for what’s ahead as I begin my Vattikuti Foundation robotic uro-oncology fellowship🤩 Grateful for this amazing opportunity 🙏 Gagan Gautam Dr Puneet Ahluwalia gagan Gopal Sharma Intuitive Medanta

📊 PROTECT trial (15-year analysis): Metastasis rates in prostate cancer by cribriform status 👇 • Cribriform+: Active monitoring 25%, Surgery 26%, RT + ADT 8% • Cribriform–: 7%, 4%, 3% 👉 Cribriform– disease = low long-term risk; Cribriform+ = high risk, mitigated by RT+ADT

🧪 LITESPARK-022 Trial Highlights ✅ Combination: Belzutifan + Pembrolizumab 🏥 Population: Post-nephrectomy cc RCC (Adjuvant) 📈 Outcome: Significant & clinically meaningful improvement in disease-free survival (DFS) 🌟Takeaway: Promising new adjuvant option in RCC management

“You only need to screen 12 patients for prostate cancer to save a life. That’s why proactive screening is so important.” Dr. Stacey Loeb speaks to Urology Times about early screening, combatting misinformation, and the importance of patient education.

🩺 We can sue doctors if their advice causes harm, but what about AI? If a chatbot like ChatGPT gives medical advice that leads to trouble, can you sue OpenAI? AI medicine is growing fast, but accountability laws are still catching up ⚖️🤖 #AIinMedicine

Lighter moments and Chai therapy after a hectic OT day 🍵 #MedantaUroOnco #TeamSpirit

I’m currently planning a project on the broader implications of AI in medicine in India, especially its medico-legal aspects. If you’re interested in contributing or collaborating on this academic exercise, let’s connect here or DM! 🤝💡

🚀 Latest tech in #RARP: 🔹 NEUROsafe – Real-time intraoperative frozen section protocol to preserve neurovascular bundles while ensuring negative margins 🔹 LASERsafe trial – Evaluates intraoperative confocal laser endomicroscopy for real-time margin assessment during RARP

VIDEO | Delhi’s toxic air isn’t just choking lungs, it’s attacking hearts too. Dr Naresh Trehan, Chairman & MD, Medanta The Medicity, explains how pollution particles enter the bloodstream, trigger inflammation, raise blood pressure, and even precipitate heart attacks. He warns,

Interacted with Prof. Prof Nikhil Vasdev at @Medanta today during a rare robotic cystectomy for a fungal infection. Grateful for the learning experience-especially insights into his work in AI and Aquablation. Truly inspiring day! 🤗 Gagan Gautam

🚨 Breakthrough alert: PlasmaSure™, a non-thermal, in-office plasma treatment for non-muscle-invasive bladder cancer, just got FDA Breakthrough Device Designation. High precision tumor ablation, minimal damage, fast recovery—truly promising for patients. #uroonco #bladdercancer

Spot On !

Hot off the press!! First reported case series of transurethral robotic en bloc resection of bladder tumour using the Virtuoso Endoscopy System (VES). Published in European Urology Oncology today! (1/n) #ERBT #UroSoMe

VES is a novel robotic surgical system that allows transurethral ERBT. The concentric tube design of the instrument arms allows controllable manipulation at a small diameter of ~1mm. This is extremely crucial to allow a two-handed surgery w/o obscuring the endoscopic view. (2/n)